Beauty Health (NASDAQ:SKIN – Get Rating) and Cytosorbents (NASDAQ:CTSO – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.
Analyst Ratings
This is a summary of recent ratings and target prices for Beauty Health and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 0 | 2 | 6 | 0 | 2.75 |
| Cytosorbents | 0 | 0 | 1 | 0 | 3.00 |
Beauty Health presently has a consensus price target of $19.50, indicating a potential upside of 55.63%. Cytosorbents has a consensus price target of $5.75, indicating a potential upside of 74.24%. Given Cytosorbents’ stronger consensus rating and higher probable upside, analysts clearly believe Cytosorbents is more favorable than Beauty Health.
Institutional & Insider Ownership
Risk and Volatility
Beauty Health has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Profitability
This table compares Beauty Health and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | 12.13% | 1.97% | 0.49% |
| Cytosorbents | -94.59% | -73.94% | -46.88% |
Earnings and Valuation
This table compares Beauty Health and Cytosorbents’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beauty Health | $365.88 million | 4.54 | $44.38 million | ($0.18) | -69.61 |
| Cytosorbents | $34.69 million | 4.15 | -$32.81 million | ($0.75) | -4.40 |
Beauty Health has higher revenue and earnings than Cytosorbents. Beauty Health is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Summary
Beauty Health beats Cytosorbents on 11 of the 14 factors compared between the two stocks.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
About Cytosorbents
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
